Ovarian cancer cells, not normal cells, are damaged by Mirk/Dyrk1B kinase inhibition

DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly

(2011) L. Litovchick et al.   GENES & DEVELOPMENT

Inactivation of Mirk/Dyrk1b Kinase Targets Quiescent Pancreatic Cancer Cells

(2011) D. Z. Ewton et al.   MOLECULAR CANCER THERAPEUTICS

Selective killing of cancer cells by a small molecule targeting the stress response to ROS

(2011) Lakshmi Raj et al.   NATURE

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

The WD40-repeat protein Han11 functions as a scaffold protein to control HIPK2 and MEKK1 kinase functions

(2010) Stefanie Ritterhoff et al.   EMBO JOURNAL

Transient arrest in a quiescent state allows ovarian cancer cells to survive suboptimal growth conditions and is mediated by both Mirk/dyrk1b and p130/Rb2

(2010) Jing Hu et al.   INTERNATIONAL JOURNAL OF CANCER

p21 promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker

(2010) Magdalena B Flak et al.   Molecular Cancer

DYRK1B-dependent autocrine-to-paracrine shift of Hedgehog signaling by mutant RAS

(2010) Matthias Lauth et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

The Kinase Mirk/dyrk1B: A Possible Therapeutic Target in Pancreatic Cancer

(2010) Eileen Friedman   Cancers

Mirk/Dyrk1B Maintains the Viability of Quiescent Pancreatic Cancer Cells by Reducing Levels of Reactive Oxygen Species

(2009) X. Deng et al.   CANCER RESEARCH

The kinase Mirk is a potential therapeutic target in osteosarcoma

(2009) C. Yang et al.   CARCINOGENESIS

Mirk Regulates the Exit of Colon Cancer Cells from Quiescence

(2009) Kideok Jin et al.   JOURNAL OF BIOLOGICAL CHEMISTRY